ViiV Healthcare
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, ViiV Healthcare sits in the top decile of US sponsors by registered trial count (#165 of 15,742 sponsors by registered trial count).
ViiV Healthcare: 182 sponsored US clinical trials, 7 recruiting.
ViiV Healthcare sponsors 182 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 147 completed. 47 of these trials are in Phase 3-4 (later-stage) and 132 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 36 trials.
Top-decile sponsor footprint
ViiV Healthcare ranks in the top decile of sponsors by registered trial count (#165 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
147 of 163 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
182 total, page 2 of 4
Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)
NCT04021290
A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants
NCT04128293
Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)
NCT04001803
Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults
NCT03945981
Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent
NCT03984838
Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study
NCT03984812
Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive
NCT03984825
Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine
NCT03836729
A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults
NCT03784079
Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)
NCT03816696
Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study
NCT03639311
To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers
NCT03441984
Real-world Insights of People With Human Immunodeficiency Virus (HIV) Infection
NCT03400293
Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)
NCT03446573
Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019
NCT03016533
Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir
NCT03095638
Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine
NCT03078556
Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers
NCT02478463
Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet
NCT02893488
A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects
NCT02859259
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
NCT02831673
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)
NCT02831764
A Study to Evaluate the Effect of High Fat Meal on Cabotegravir
NCT02799264
Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)
NCT02741557
Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations
NCT02738931
A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176
NCT02715479
A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)
NCT02674581
A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects
NCT02666053
A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone
NCT02666001
Taste Properties of HIV Inhibitor
NCT02608918
A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers
NCT02634073
Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates
NCT02578277
THE Effect OF Cyp3a5 Genotype ON THE Pharmacokinetics OF Maraviroc
NCT02625207
A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects
NCT02576119
Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects
NCT02539576
Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment
NCT02354937
Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults
NCT02386098
A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)
NCT02480881
A Open-label, Drug-Drug Interaction With Maraviroc (DDI)
NCT02480894
Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects
NCT02411435
A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers
NCT02354950
Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen
NCT02478632
Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults
NCT02415595
Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)
NCT02422797
Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)
NCT02429791
Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir
NCT02345707
Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects
NCT02373930
Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects
NCT02467335
A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)
NCT02277600
Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.
NCT02206711
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 98 |
| Phase 2 | 34 |
| Phase 3 | 39 |
| Phase 4 | 8 |
What is open in the ViiV Healthcare pipeline
7 recruiting of 182 indexed (4% open); 147 completed (81%).
Phase mix: 47 late (III/IV) vs 132 early (I/II) (early-phase heavy).
Top condition: HIV Infections (36 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
ViiV Healthcare: open-pipeline peers nationwide
Peers matched on 182 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
ViiV Healthcare sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 182 trials (± recruiting share)
- Fox Chase Cancer Center · 183 trials · 16% recruiting
- Abbott · 181 trials · 0% recruiting
- Children's Mercy Hospital Kansas City · 184 trials · 11% recruiting
- Baylor Research Institute · 180 trials · 17% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Aldeyra Therapeutics · 4% recruiting · 26 trials
- DexCom · 4% recruiting · 26 trials
- MaineHealth · 4% recruiting · 26 trials
- Medtronic Spinal and Biologics · 4% recruiting · 26 trials
Related
What to do with this ViiV Healthcare page
182 registered trials is a research-attention snapshot, not an endorsement of ViiV Healthcare or any single study.
- 7 of ViiV Healthcare's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition ViiV Healthcare studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. ViiV Healthcare pipeline card: 182 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.